ArticleObesity science & practice2025
Impact of Anti-obesity Medication Initiation and Duration on Weight Loss.
Article in Obesity science & practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.Diabetes, obesity & metabolism · 2026Review
- Twenty-Four Month Outcomes From a Real-World Telehealth Obesity Treatment Clinic Using Obesity Medications.Obesity (Silver Spring, Md.) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Real-world studies of anti-obesity medication (AOM) use have shown lower adherence and persistence than clinical trials; however, the impact of this reduced adherence in real-world settings remains largely unexplored. This study aimed to evaluate the effects of AOM use, timing of initiation, and duration on 18-month weight loss outcomes in comprehensive obesity care practice, offering critical insights into the role of adherence in optimizing treatment efficacy. Methods: This retrospective cohort study assessed the electronic health records of adults with a body mass index (BMI) ≥ 30 kg/m Results: This study of 1282 participants showed that AOM users had greater weight reduction than non-users. Long- and short-duration AOM users experienced significantly more weight loss than short-duration users, with no difference between early and delayed starters. Second-generation semaglutide users were more likely to reach the 20% weight loss milestone, especially with longer use. Conclusion: Long-term AOM use significantly improved weight loss in comprehensive obesity care. Furthermore, the success of non-AOM users highlights the value of intensive behavioral programs, indicating the need for personalized treatment to optimize cost-effectiveness and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.